MARKET

CASI

CASI

Casi Pharmaceuticals Inc
NASDAQ
3.255
-0.205
-5.92%
Opening 13:27 05/23 EDT
OPEN
3.360
PREV CLOSE
3.460
HIGH
3.360
LOW
3.220
VOLUME
5.25K
TURNOVER
0
52 WEEK HIGH
8.48
52 WEEK LOW
1.850
MARKET CAP
43.62M
P/E (TTM)
-1.4276
1D
5D
1M
3M
1Y
5Y
Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis
Healthcare Eli Lilly inks radiopharma deal worth up to $ with Aktis Oncology. Aktis will receive a $60M upfront payment. Eli Lilly will leverage Aktis’ radiopharmaceutical platform to develop cancer-targeting drugs.
Seeking Alpha · 2d ago
Weekly Report: what happened at CASI last week (0513-0517)?
Weekly Report · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-MakeMyTrip, WaFd, Bolt Biotherapeutics
The benchmark S&P 500 .SPX and the Nasdaq .IXIC touchedrecord highs on Wednesday. A lower-than-expected increase in a key inflation metric buttressed hopes that the Federal Reserve will cut interest rates this year. The Dow Jones Industrial Average was up.
Reuters · 05/15 18:05
Health Care Sector Update for 05/15/2024: BIIB, GDRX, CASI
NASDAQ · 05/15 17:52
BUZZ-U.S. STOCKS ON THE MOVE-Dell, Biogen, Canoo
The benchmark S&P 500 .SPX and the Nasdaq .IXIC touched record highs on Wednesday. A lower-than-expected increase in a key inflation metric buttressed hopes that the Federal Reserve will cut interest rates this year. Dell, Biogen, Canoo and Deckers Outdoor Corp are among the day's top stocks.
Reuters · 05/15 16:41
CASI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/15 15:57
CASI Pharmaceuticals Price Target Cut to $6.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 05/15 15:57
HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $6
Benzinga · 05/15 15:46
More
About CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Webull offers CASI Pharmaceuticals Inc stock information, including NASDAQ: CASI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CASI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CASI stock methods without spending real money on the virtual paper trading platform.